anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:The titled safe spherical fine powder, consisting of cellulose acetate having a specific average spherical diameter and substitution degree, and capable of remarkably improving properties such as adhesion, covering properties, moldability, etc. by incorporating in a powdery cosmetic, etc. without irritancy to the skin. CONSTITUTION:A spherical powder obtained by forming a solution of cellulose acetate, having <=30mu average spherical diameter or containing 0-10wt% spheres having >=30mu average spherical diameter and <=74mu average spherical diameter, <=25mu average spherical diameter and 1.7-3.0 substitution degree in an organic solvent and an aqueous dispersion into a suspended solution in a homogenizer, etc., and evaporating the organic solvent and water, or spray drying the solution of the cellulose acetate in the organic solvent into spherical fine powder. The cellulose acetate has lipophilic and hydrophilic groups together, is effective as a dispersion medium for dyestuffs, and can be uniformly kneaded and dispersed even in a lipstick. The pure white color thereof as a pigment base is excellent in enhancing the hue of a colorant.
The protocol will consist of starting patients on 15 g of L glutamine twice daily by mouth. This is the same dose that is used to treat patient with sickle cell anemia. They will be given this medication for a total of 3 months. Their other medications will remain the same. At the conclusion of the 3 months, the patients will be taken off of the glutamine and will continue their other medications. The investigators will monitor the patients an additional 3 months (6 months after the initiation of the study) off the L-glutamine. In this manner, the investigators will have a washout period. The outcome will be a comparison of the results before the initiation of the L-glutamine, to the results after treatment, and after the washout.

Data analysis will consist of comparing the patient's fasting glucose and hemoglobin A1c values. The investigators will also check the levels of fructosamine. This is a standard test that is done in any clinical laboratory. To help determine the mechanism for the L-glutamine effect, the investigators will also measure the complete blood count, chemistry panel, hepatic function panel, urine micro-albumin, patients' weight, and waist circumference. The investigators will use the Student t-test for statistical analysis. Significance will be tested at the 0.05 level.

The investigators will collect demographic information on the patients in the study. Age, sex, duration of diabetes, smoking history, and race will be noted. The investigators will use regression analysis to determine whether these factors have any effects on the observed results.
Children and families in the intervention group will received the FAMILY program developed according to evidence-based guidelines.The intervention content regarding healthy sleep will emphasize the importance of having a consistent sleep schedule, establishing a regular bedtime routine, and creating an environment only for sleeping. The physical activity content will emphasize at least 60 minutes/day of moderate-to-vigorous intensity physical activity, reduction of sedentary behavior, and screen time limited to 2 hours/day. The nutrition content will emphasis the replacement of sugar-sweetened beverages, increased fruit and vegetable as well as water intake, consumption of regular meals, and reduction of discretionary food groups.
Like most xanthines, caffeine is rapidly absorbed and distributed in all body tissues and fluids, including the CNS, fetal tissues, and breast milk.

Caffeine is cleared rapidly through metabolism and excretion in the urine. The plasma half-life is about 3.0 hours. Hepatic biotransformation prior to excretion results in about equal amounts of 1-methyl-xanthine and 1-methyluric acid. Of the 70% of the dose that has been recovered in the urine, only 3% was unchanged drug.

The bioavailability of the caffeine component for butalbital, aspirin, and caffeine is equivalent to that of a solution except for a slightly longer time to peak. A peak concentration of 1660 ng/mL was obtained in less than an hour for an 80 mg dose (see OVERDOSAGE for toxicity information).
PROBLEM TO BE SOLVED: To simply obtain the subject compound useful as an intermediate for producing a pharmaceutically active compound in high optical yield and high chemical yield by resolving a salt of a specific racemic compound with a chiral and non-racemic amino compound. SOLUTION: This chiral and non-racemic compound is represented by formula I (R<1> is H, F, Cl, etc.; R<2> is H, F, a 1-7C alkyl, etc.), e.g. (S)-(4-(4-cyanophenyl)-4- methyl-2,5-dioxoimidazolidin-1-yl)acetic acid. The compound of formula I is obtained by converting a carbonyl compound represented by formula II into hydantoin under conditions of Bucherer reaction, alkylating the hydantoin by using a haloacetic acid ester represented by formula III (R<3> is a 1-6C alkyl or benzyl; X is Cl, Br or I) and further converting the resultant ester to an acid of formula I.
An apparatus (30) comprises a unitary construction which includes both a coating chamber (32) adapted to receive a person to be coated with a predetermined substance which is preferably provided in the form of a liquid that is received in a reservoir (60).  The coating chamber (32) is further provided with a plurality of spray columns (36) which are supported for pivotal movement through predetermined arcs under the action of a pneumatic cylinder.  Each spray column (36) includes an inner tubular passageway which receives liquid from the reservoir (60) under the action of compressed air supplied by the air compressor (62) through a tank (64), and an outer tubular passageway which receives compressed air from the manifold (68).  Each spray column (36) is provided with a plurality of nozzles.  Each nozzle receives compressed air from the outer tubular passageway through a quick disconnect, and receives liquid from the inner tubular passageway through a quick disconnect.  A check valve prevents reverse flow of liquid back through the quick disconnect.
In this cluster randomized control trial design, the experimental arm refers to the 12 study sites that are randomly assigned to receive the clinician training intervention. The intervention is a clinician training using standardized patient actors to improve communication and empathy skills of health care workers who deliver PrEP to adolescent girls and young women to prevent HIV.
This proposed study is a multi-practice, cluster-design, prospective randomized controlled trial with a total study intervention period of 12 months. This prospective randomized controlled trial will assess the effectiveness of performing NDMPs by the registered nurse supervised by a physician (the intervention group) in comparison with usual diabetes care (the usual care group) for adults with diabetes in primary care settings. The study population will be recruited from University of Pittsburgh Medical Center Community Medicine Inc. (CMI) primary care practices in urban and suburban communities surrounding Pittsburgh, PA. Among these CMI practices, ten practices receive diabetes education services from University of Pittsburgh Diabetes Institute and will be the intervention group. These diabetes education services will be enhanced by the addition of NDMPs intervention. In addition, we will select another 10 CMI practices to be the usual care group. This group receives standard diabetes education with no use of NDMPs. One-hundred and fifty participants will be recruited across practices within each study group (i.e., 300 in total). Outcomes assessed in this study include clinical outcome and process measures as recommended by ADA, participants' quality of life, treatment satisfaction, and medication adherence, and providers' satisfaction, and costs/expenditure. Assessments will be done at baseline, and three and 12 months after the study entry. Analysis of the study outcomes will be based on intention-to-treat to determine (1) within-group differences between the baseline and follow-up visits, and (2) between-group differences between the intervention group and the usual care group.
NEW MATERIAL:The compound of formulaI(R1 is H, lower alkyl, etc.; R2 is H or lower alkyl; R3 is H, halogen, alkyl or alkenyl; R4 and R5 are H, lower alkyl or together form a ring; R6 is H, alkyl, alkenyl, alkynyl, aralkyl, acyl, etc.; A is H or oxo; the dotted line is single or double bond). EXAMPLE:2-(8-Chloro-1,2-dihydro-2,2-dimethylquinolin-6-yl) propionic acid ethyl ester. USE:Antiphlogistic, antipyretic and analgesic agent. PROCESS:The compound of formulaIcan be prepared by reacting the compound of formula II with the compound of formula III (X1 is halogen) in an inert organic solvent in the presence of a tertiary amine (e.g. triethylamine), cuprous chloride and if necessary powdery copper under heating, and thermally cyclizing the resultant compound of formula IV in an inert solvent in the presence of zinc chloride, etc.
Psoriasis is a chronic, autoimmune skin disease characterized by the deregulated secretion of inflammatory factors in multiple organs. The aberrant activation of signal transducer and activator of transcription 3 (STAT3) signaling pathway mediated by cyclin-dependent kinase 9 (CDK9) is vital for the pathology of psoriasis, leading to the accumulation of inflammatory factors and the progression of skin damage. In this study, we explored the effect of CDK9 inhibition on attenuating the secretion of inflammatory factors and alleviating skin damage in psoriasis models both in vitro and in vivo. Results showed that Atuveciclib, a highly selective CDK9 inhibitor, significantly relieved skin lesions in Imiquimod (IMQ)-induced mice models by lowering the expression of CDK9 and p-RNA Pol II Ser2. Meanwhile, Atuveciclib significantly inhibited STAT3 phosphorylation in mice skin and reduced the levels of key inflammatory cytokines in mice skin, plasma and spleen. In addition to suppressing the secretion of inflammatory cytokines, Atuveciclib ablated the activation of STAT3 induced by tumor necrosis factor-α (TNF-α)/interferon-γ (IFN-γ). Overall, our findings indicated that the overexpression and hyperfunction of CDK9 promote the progression of psoriasis. Moreover, Atuveciclib interfered with the abnormal STAT3 signaling pathway through the inhibition of CDK9, which ultimately ameliorated psoriatic-like skin inflammation. These suggested that CDK9 inhibition is a potential strategy for batting psoriasis.
All individuals in the Case group (i.e., only the subjects who had lost weight) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO twice a day (BID) for 14 days. Subjects in the case group were in the study for 3 months.
Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.
Patients receive ifosfamide IV continuously on days 1-4, vinorelbine ditartrate IV over 6-10 minutes on days 1 and 5, and filgrastim SC or IV beginning on day 6 and continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of unacceptable toxicity or disease progression. Patients then receive 2 more courses of ABVE-PC in the absence of unacceptable toxicity or disease progression.
The proposed clinical trial will evaluate the role of genetic factors including single nucleotide polymorphisms from cyclooxygenase (COX) - 2 gene on acute pain after tissue injury and the analgesic effect of a COX inhibitor. Patients will be healthy volunteers scheduled for the surgical removal of impacted third molars. Genotyping will be performed before surgery and patients stratified to treatment with a COX inhibitor in this protocol or to other protocols examining different polymorphisms.

Under local anesthesia, 2 mandibular third molars will be removed. Microdialysis sampling in the extraction socket will be performed with pre- and post-surgical biopsies. Patients will receive a COX inhibitor as an analgesic drug for the post-operative pain. Outcomes evaluated will include clinical pain response, gene expression profile using microarray and quantitation of related proteins after oral surgery and the interaction of these factors with analgesia by a COX inhibitor. By studying these responses in patient samples for each genotype (non-variant homozygote, heterozygote and variant homozygote) from the COX-2 gene, we will attempt to replicate and extend previous findings on the role of genetic factors in the inflammatory process, clinical pain and variation in response to analgesic drugs.
Bilateral sham point acupuncture will be performed intra-operatively. Patient will be sent home with a wrist sham band matching in appearance of acupressure bands without the acupressure function, which is to remain on for 24 hours post operatively.
We will measure serum renin values every six hours. If the measured renin concentration increases by more that 20% compared with the last value, the target mean arterial pressure (MAP) will be elevated to 75-80 mmHg. If the subsequent renin level is still rising, the target MAP will be further raised to 85-90 mmHg and the addition of inotropes will be considered. If the first subsequent renin level decreases or increases by ≤20%, the target MAP will be kept at 75-80 mmHg. If the renin level at the subsequent measurement after reaching the highest step of management protocol is still increasing, a failure of the intervention will be declared, the target MAP will return to 65-70 mmHg. If renin level further decreases or increases ≤20% for two consecutive measurements, we will downgrade the target MAP to the previous step.
Healthcare Professionals who attended at least one of the five training courses on ethics consultation provided by the Clinical Ethics Committee. They will receive a survey of 20 multiple-choice questions and supplemented by free-text questions.
A method and composition for inactivating both naked genetic material such as RNA and DNA and inactivating mechanical delivery vectors in a treatment space external of the human body. To practice the method, apply a mist of lipid molecule degrading agent effective against viral membranes with lipid molecules. Then apply an inactivaor of spike proteins and other viral residues. Next, reduce the threat of transmitting genetic material by applying inactivators of mechanical transport vectors such as mold, yeast, and bacteria. Further, pretreat the treating space to receive enzymatic agents by applying a surface detoxifying agent in quantity sufficient to inactivate substances detrimental to enzymes that break the naked viral genetic material. Then, apply preparatory enzymes that degrade microorganisms and their cellular components. Finally, apply enzymes for breaking the naked viral genetic material, as present.
The invention discloses a new Eimeria tenella heat shock protein 60 (Et HSP60) gene. The cloning number is ZB2-D07, the total length is 1802 bp, and the Et HSP60 gene contains a 1455 bp complete open reading frame (ORF) and can code 484 amino acids (Genbank accession number: FJ911605). The gene is connected with a prokaryotic expression vector pET28a(+) to construct a prokaryotic expression recombinant plasmid pET28a(+)-Et HSP60 and is expressed in an escherichia coli system. SDS-PAGE (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis) is carried out by purifying the recombinant protein pET28a(+)-Et HSP60, and then the recombinant protein pET28a(+)-Et HSP60 is transferred to a PVDF (Polyvinylidene Fluoride) membrane. The antiserum of immuned chicken orally taking E. tenella oocyst is taken as a primary antibody, and goat-anti-chicken IgG (immunoglobulin G) is taken as a secondary antibody to carry out Western-blot analysis. The analysis result shows that the recombinant protein pET28a(+)-Et HSP60 has certain antigenicity and can be used for preparing a medicine for resisting chicken coccidiosis and a vaccine resisting chicken coccidiosis.
Background/Objective: This study examined the anti-obesity effect of royal jelly (RJ) in rats fed with a high-fat diet by targeting the major pathways involved in adipogenesis and lipolysis. In addition, it examined whether this effect is AMPK-dependent. Methods: Five groups of adult male albino rats were used (n = 6 each as 1); the control rats were fed with a normal diet (2.9 kcal), and the other groups were as follows: control + RJ (300 mg/kg), HFD (4.75 kcal), HFD + RJ (300 mg/kg), and HFD + RJ (300 mg/kg) + dorsomorphin (an AMPK inhibitor) (0.2 mg/kg). Results: RJ was administered orally to all rats. With no changes in food and energy intake, RJ significantly reduced gains in body weight, fat weight, body mass index (BMI), the Lee index, abdominal circumference (AC), and the adiposity index (AI). It also reduced fasting glucose and insulin levels, HOMA-IR, and the circulatory levels of free fatty acids (FFAs), triglycerides, cholesterol, and LDL-c in the HFD-fed rats. RJ also increased serum glycerol levels and adiponectin levels, but reduced the serum levels of leptin, IL-6, and TNF-α. Moreover, RJ reduced the secretion of IL-6 and TNF-α from isolated WAT. At the tissue level, the HFD + RJ rats exhibited a smaller adipocyte size compared to the HFD rats. At the molecular level, RJ increased the phosphorylation of AMPK, SREBP1, and ACC-1 and increased the mRNA and protein levels of HSL and ATG in the WAT of the HFD rats. In concomitance, RJ increased the mRNA levels of PGC-α1, reduced the protein levels of PPARγ, and repressed the transcriptional activities of PPARγ, SREBP1, and C/EBPαβ in the WAT of these rats. All the aforementioned effects of RJ were prevented by co-treatment with dorsomorphin. Conclusions: RJ exerts a potent anti-obesity effect in rats that is mediated by the AMPk-dependent suppression of WAT adipogenesis and the stimulation of lipolysis.
The active ingredient in Famotidine Injection is a histamine H2-receptor antagonist. Famotidine is N'-(aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide. The empirical formula of famotidine is C8H15N7O2S3 and its molecular weight is 337.45. Its structural formula is:

Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol.

Famotidine Injection is supplied as a sterile solution, for intravenous use only, in plastic single dose GALAXY containers. Each 50 mL of the premixed, iso-osmotic intravenous injection contains 20 mg Famotidine, USP, and the following inactive ingredients: L-aspartic acid 6.8 mg, sodium chloride, USP, 450 mg, and Water for Injection. The pH ranges from 5.7 to 6.4 and may have been adjusted with additional L-aspartic acid and/or with sodium hydroxide.

The GALAXY plastic container is fabricated from a specially designed multilayer plastic. Solutions are in contact with the polyethylene layer of the container and can leach out certain chemical components of the plastic in very small amounts within the expiration period. The suitability and safety of the plastic have been confirmed in tests in animals according to the USP biological tests for plastic containers, as well as by tissue culture toxicity studies.
1. Technical Result Increase in efficiency of treatment of cerebral insufficiency. 2. Essence This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks, which are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementia, and in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia and affective disorders. In a particular aspect, the present invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment. 3. Field of Application Medicine.
Participants in the placebo arm will take 15 capsules of placebo. Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances. Participants will receive a twelve-week supply of blinded drug capsules in the mail from Johnson Compounding Pharmacy. The anticipated duration of the study is at least 8 weeks and no more than 12 weeks.
An imipenem-resistant pseudomonas aeruginosa bacteriophage and application thereof in treating imipenem-resistant pseudomonas aeruginosa infection. The invention relates to a broad phage obtained by separation and a therapeutic application of the broad phage. The present inventors have conducted extensive studies to provide a biological means for treating clinical imipenem-resistant pseudomonas aeruginosa infection. The result is to separate and obtain a square spectrum drug-resistant pseudomonas aeruginosa bacteriophage phi A392. It can kill drug-resistant pseudomonas aeruginosa effectively in vivo and in vitro. The inventor conducts further research based on the purpose of providing a novel anti-infection treatment means, and the phage can be used for cracking multiple strains of clinical isolation of imipenem-resistant pseudomonas aeruginosa in vitro and in vivo. The invention proves the superiority and feasibility of the bacteriophage as a therapeutic substance in clinical anti-pseudomonas aeruginosa infection treatment, and provides a new clinical treatment means for resisting imipenem pseudomonas aeruginosa infection.
Seventeen preschool children (G1), with no motor impairments, from a private school. The children in G1 performed the synthetic test before the computerised test.
PURPOSE:To obtain the subject preventive and remedy by including SOD in a liposome having electrically neutral or negative membrane and using the obtained SOD-containing lipsome as an active component. CONSTITUTION:The objective agent contains, as an active component, an SOD- containing liposome produced by including SOD(superoxide dismutase) in a liposome having an electrically neutral membrane produced by using a neutral glycerophospholipid such as phosphatidylcholine, a sphingolipid such as sphingomyelin or natural lecithin or having an electrically negative membrane produced by using the above component in combination with a 10-20C higher fatty acid phosphoric acid ester such as dicetyl phosphate. Preferably, the amount of the lipid is 0.5-50 pts.wt. per 1 pt.wt. of SOD and that of aqueous medium is 20-200 pts.wt. per 1 pt.wt. of the phospholipid. The drug exhibits excellent DIC preventing and remedying effect and improves the result of organ transplantation.
Subjects will receive IV methadone 0.2 mg/kg (maximum dose 20mg) via an infusion pump over 15 minutes while undergoing continuous monitoring. Additional IV methadone may be given during the case per the anesthesiologist's discretion, but the total dose may not exceed 20mg.
1. For the current minimally invasive total knee arthroplasty, due to the limitation of the surgical field of view and the scope of operation, and the error of the intraoperative osteotomy saw, it can cause intraoperative damage to ligaments, nerves and blood vessels, postoperative lower limb force lines and prosthesis position Poor, abnormal movement and force of the patellofemoral joint and tibiofemoral joint after surgery can easily lead to clinical symptoms such as rapid wear of the prosthesis, short service life, postoperative knee pain, and even possible problems with surgical failure and revision. Developed a robot for minimally invasive total knee replacement surgery. Minimally invasive total knee arthroplasty is performed by surgical robot and manual operation. According to intraoperative and postoperative imaging observations, the position of the prosthesis, and the evaluation of soft tissue balance during and after the operation, the two methods are compared with the surgical robot and manual operation. Kind of surgery.
2. To prepare for the subsequent CFDA application of the minimally invasive total knee replacement robot system.